CCND1 G870A polymorphism and risk for head and neck cancer: a meta-analysis

CCND1 plays a critical role in cell cycle control and may contribute to head and neck cancer. We performed a meta-analysis of eleven case–control studies that examined the association between CCND1 G870A polymorphism and head and neck cancer risk. Overall, no significant association of this polymorphism with head and neck cancer was found (for AA vs. GG: OR = 0.96, 95% CI = 0.59–1.58, P < 0.01 for heterogeneity; for GA vs. GG: OR = 1.00, 95% CI = 0.74–1.35, P < 0.01 for heterogeneity; for the dominant model GA/AA vs. GG: OR = 0.98, 95% CI = 0.69–1.39, P < 0.01 for heterogeneity; for the recessive model AA vs. GG/GA: OR = 0.94, 95% CI = 0.66–1.33, P < 0.01 for heterogeneity). In subgroup analysis by ethnicity, we also did not find any significant association in European and Asians populations. All the results were not materially altered in any genetic model after the studies which did not fulfill Hardy–Weinberg equilibrium were excluded. In conclusion, our meta-analysis strongly suggested that the CCND1 G870A polymorphism is not associated with head and neck cancer risk.